What is axitinib/axitinib? Analysis of indications and treatment principles

Axitinib is an oral small molecule targeted drug that is a tyrosine kinase inhibitor (TKI). It reduces the blood supply of tumors and inhibits the growth and spread of tumor cells by inhibiting a variety of receptors related to tumor angiogenesis. Axitinib is mainly used to treat advanced or metastatic renal cell carcinoma (RCC), especially in patients after failure of first-line therapy. It not only effectively delays tumor progression, but also improves patients' quality of life.

The mechanism of action of axitinib is mainly by inhibiting vascular endothelial growth factor receptor (VEGFR) and other related receptors such as PDGFR (platelet-derived growth factor receptor) and c-KIT, blocking tumor angiogenesis and cutting off the blood supply of tumor cells. Tumors need nutrients and oxygen through the formation of new blood vessels, and axitinib can effectively prevent tumor growth by inhibiting these key tyrosine kinase receptors. By reducing angiogenesis, axitinib not only reduces the oxygen supply to tumor cells, but also reduces tumor invasiveness and delays disease progression.

Axitinib is mainly used to treat patients with advanced renal cell carcinoma (RCC), especially those whose disease has progressed after first-line treatment (such as sunitinib, sorafenib and other drugs). As a second-line treatment, axitinib has demonstrated its efficacy and tolerability in multiple clinical studies. Through its targeting effect, axitinib can effectively prolong the progression-free survival (PFS) and overall survival (OS) of patients. In addition, axitinib is also used in the treatment of other malignant tumors closely related to angiogenesis, such as certain types of soft tissue sarcomas.

Reference materials:https://en.wikipedia.org/wiki/Axitinib